Cognizant Technology Solutions (CTSH) Earnings Date & Reports
Cognizant Technology Solutions is a multinational IT services provider that offers a range of consulting and business process outsourcing services... Show more
CTSH is expected to report earnings to fall 1.43% to $1.38 per share on August 05
Cognizant (CTSH) Q1 2026 Earnings Recap: EPS Beats on Bookings Surge
Key Takeaways
- Cognizant reported Q1 2026 revenue of $5.413 billion, up 5.8% year-over-year (YoY), landing in the upper half of prior guidance.
- Adjusted diluted earnings per share (EPS) of $1.40 beat consensus estimates of $1.33, reflecting 13.8% YoY growth.
- Trailing twelve-month (TTM) bookings reached $29.6 billion, up 11% YoY, with Q1 bookings jumping 21% including seven large deals.
- Adjusted operating margin held steady at 15.6%, up 10 basis points YoY; full-year guidance raised to 16.0%-16.2%.
- Launched Project Leap to drive AI investments and productivity, targeting $200-$300 million in 2026 net savings.
- Declared quarterly dividend of $0.33 per share; repurchased $427 million in shares.
Earnings Context and Why It Matters
As a leading IT services provider, Cognizant's Q1 2026 earnings offer critical insights into demand for digital transformation, AI adoption, and outsourcing amid economic uncertainty. The quarter ended March 31, 2026, highlights the company's resilience in Financial Services while exposing softness in Health Sciences. Investors watch these results closely for signals on deal wins, margin discipline, and AI strategy execution, which could influence peers like Accenture and Infosys. Strong bookings underscore potential revenue visibility, making this report pivotal for assessing 2026 growth trajectory in a competitive landscape.
Cognizant delivered revenue of $5.413 billion for the first quarter ended March 31, 2026, a 5.8% increase from $5.115 billion in Q1 2025, or 3.9% in constant currency (CC). This aligned closely with consensus estimates around $5.41 billion and fell in the upper half of the company's guided range of $5.36-$5.44 billion.
Adjusted diluted EPS reached $1.40, up 13.8% YoY from $1.23, exceeding Wall Street expectations of $1.33 by about 5%. GAAP EPS was $1.39, up 3.7% YoY. Adjusted operating margin expanded slightly to 15.6% from 15.5%, despite GAAP margin contracting to 15.6%.
Bookings momentum impressed, with Q1 growth of 21% YoY driven by seven large deals (including one mega deal), boosting TTM bookings to $29.6 billion and a book-to-bill ratio of about 1.4x. Segment-wise, Financial Services led with 12.4% YoY revenue growth to $1.644 billion, while Health Sciences grew just 0.5% to $1.579 billion.
Guidance for full-year 2026 revenue remains $22.11-$22.64 billion (4.0%-6.5% CC growth), with Q2 at $5.45-$5.52 billion. Adjusted operating margin outlook improved to 16.0%-16.2% (20-40 bps YoY expansion), and adjusted EPS to $5.63-$5.77, aided by Project Leap efficiencies.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Despite the EPS beat and robust bookings, CTSH shares dipped in pre-market trading following the April 29 release, reflecting investor focus on revenue growth moderating to 3.9% CC amid cautious Q2 guidance. Sentiment remains mixed, with positives from deal pipeline and AI initiatives offset by softer Health Sciences and broader IT spending concerns. Analysts maintain a generally favorable outlook, citing raised margin guidance as a margin of safety.
Forward Outlook and Key Factors to Monitor
Cognizant's unchanged full-year revenue guidance signals steady demand, but investors should track Q2 execution within the $5.45-$5.52 billion range. The raised adjusted operating margin target to 16.0%-16.2% hinges on Project Leap, a restructuring initiative funding AI via workforce optimization and productivity gains, with net savings of $200-$300 million expected in 2026 despite upfront costs.
Bookings visibility remains strong at a 1.4x book-to-bill, particularly in Financial Services and emerging AI deals. Watch segment dynamics: Financial Services' momentum could offset Health Sciences' headwinds from client budget scrutiny.
Broader catalysts include AI adoption rates, as Cognizant positions as an "AI builder" through partnerships and investments. Capital returns continue with $1.5 billion left for repurchases and a steady $0.33 quarterly dividend. Macro factors like interest rates and tech spending will shape outcomes, alongside peer comparisons for industry health.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a provider of information technology services
Industry InformationTechnologyServices